Microbiological features of bronchial asthma and chronic obstructive pulmonary disease during remission

Abstract

Background: Bronchial asthma and chronic obstructive pulmonary disease are currently the fifth leading cause of death in the world. The combination of bronchial asthma and chronic obstructive pulmonary disease seems to be a unique disease resulting from the interaction of genetic, pathological and functional factors.

Aim: Study of clinical and functional parameters, bacterial spectrum in patients with combination of asthma and chronic obstructive pulmonary diseases bronchitis and non-bronchitis types.

Methods: Clinical and functional examination of 69 patients with obstructive respiratory diseases, of which 49 patients with asthma combined with chronic obstructive pulmonary disease of bronchitis and non-bronchitis types. The microbiological spectrum of nasal pharynx induced by sputum was studied.

Results: The following microorganisms were isolated: Staphylococcus (S. aureus, S. epidermidis), Neisseria subflava, Streptococcus (α-haemolyticus, β-haemolyticus), Streptococcus pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Branhamella catarrhalis, Enterococcus, Haemophilus influenzae, Candida albicans, Aspergillus spp., Actinomyces spp., Cladosporium, Penicillium, and others.

Conclusion: A more pronounced quantitative content and a more diverse microbial landscape leads to a more severe course of the disease asthma combined withchronic obstructive pulmonary disease especially of the bronchitis type.

Keywords

microbiological spectrum / bronchial asthma / chronic obstructive pulmonary diseases

References

[1] World Health Organization. World Health Statistics 2012. Geneva: WHO Press; 2013.

[2] Diagnosis of Diseases of Chronic Airflow Limitation: Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS). Global Strategy for Asthma Management and Prevention, 2014. Доступно по: http//www.ginasthma.org. Ссылка активна на 16.10.2018.

[3] Menezes AM, Montes de Oca M, Pérez-Padilla R, et al.; PLATINO Team. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest. 2014;145(2):297–304. doi: 10.1378/chest.13-0622.

[4] Diaz-Guzman E, Khosravi M, Mannino DM. Asthma, chronic obstructive pulmonary disease, and mortality in the U.S. population. COPD. 2011;8(6):400–407. doi: 10.3109/15412555.2011.611200.

[5] Tho NV, Park HY, Nakano Y. Asthma-COPD overlap syndrome (ACOS): A diagnostic challenge. Respirology. 2016;21(3):410–418. doi: 10.1111/resp.12653.

[6] Louie S, Zeki AA, Schivo M, et al. The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. Expert Rev Clin Pharmacol. 2013;6(2):197–219. doi: 10.1586/ecp.13.2.

[7] Nakawah MO, Hawkins C, Barbandi F. Asthma, chronic obstructive pulmonary disease (COPD), and the overlap syndrome. J Am Board Fam Med. 2013;26(4):470–477. doi: 10.3122/jabfm.2013.04.120256.

[8] Mauad T, Dolhnikoff M. Pathologic similarities and differences between asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2008;14(1):31–38. doi: 10.1097/MCP.0b013e3282f19846.

[9] Eisner MD, Balmes J, Katz PP, et al. Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease. Environ Health. 2005;4(1):7. doi: 10.1186/1476-069X-4-7.

[10] Stampfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol. 2009;9(5):377–384. doi: 10.1038/nri2530.

[11] John G, Kohse K, Orasche J, et al. The composition of cigarette smoke determines inflammatory cell recruitment to the lung in COPD mouse models. Clin Sci (Lond). 2014;126(3):207–221. doi: 10.1042/CS20130117.

[12] Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347(7):465–471. doi: 10.1056/NEJMoa012561.

[13] Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359(22):2355–2365. doi: 10.1056/NEJMra0800353.

[14] Лабинская А.С., Блинкова Л.П., Eщина А.С. Частная медицинская микробиология с техникой микробиологических исследований. / Под ред. А.С. Лабинской. — М.: Медицина; 2005. — 598 с. [Labinskaya AS, Blinkova LP, Eshchina AS. Chastnaya meditsinskaya mikrobiologiya s tekhnikoj mikrobiologicheskikh issledovanij. Ed by A.S. Labinskaya. Moscow: Meditsina; 2005. 598 s. (In Russ).]

[15] Mallia P, Footitt J, Sotero R, et al. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(11):1117–1124. doi: 10.1164/rccm.201205-0806OC.

[16] Seemungal T, Harber-Owen R, Bhowmik A. et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(9):1618–1623. doi: 10.1164/ajrccm.164.9.2105011.

RIGHTS & PERMISSIONS

Smirnova-Saprytskaya M.Y., Osipova G.L., Ospelnikova T.P., Danilina G.A., Zykov K.A.